Publications by authors named "Juliana Watson"
Article Synopsis
- This study examined the effectiveness and safety of stereotactic brachytherapy (SBT) for treating low-grade gliomas (WHO grade II) in 106 patients at the University of Munich from 1997 to 2011.
- The 5- and 10-year overall survival rates were found to be 79% and 62%, respectively, with a median follow-up of nearly 10 years, and a low complication rate of 16%.
- The findings suggest that SBT is a minimally invasive option that provides a positive outcome and can be used either as a primary treatment or alongside surgery for selected patients with low-grade gliomas.
Background: Outcome and toxicity profiles of salvage stereotactic ablative radiation strategies for recurrent pre-irradiated brain metastases are poorly defined. This study compared risk-benefit profiles of upfront and salvage iodine-125 brachytherapy (SBT) for small brain metastases. As the applied SBT treatment algorithm required histologic proof of metastatic brain disease in all patients, we additionally aimed to elucidate the value of biopsy before SBT.
View Article and Find Full Text PDFBackground: The aim of this study was to provide an outcome and toxicity profile of salvage low-dose-rate iodine-125 (I-125) stereotactic brachytherapy (SBT) in patients with small, circumscribed malignant glioma recurrences.
Methods: Patients with malignant glioma recurrences consecutively undergoing salvage SBT from 2003 to 2011 were identified from our prospective tumor database. SBT was considered a potentially suitable treatment strategy for adult mostly multimodally pretreated patients (Karnofsky score of ≥ 70) with biopsy-proven, circumscribed, small (diameter ≤ 3.